MedTrace Logo

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients

NCT02879760 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-10-06

No results posted yet for this study

Summary

This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at least 1 cycle of platinum based chemotherapy and/or at least one treatment of PD-1 or PD-L1 antibody targeted therapy.

Conditions

Interventions

BIOLOGICAL

Ad-MAGEA3

Intramuscular injection

BIOLOGICAL

MG1-MAGEA3

Intravenous infusion

BIOLOGICAL

Pembrolizumab

Intravenous infusion

Sponsors & Collaborators

  • Turnstone Biologics, Corp.

    lead INDUSTRY

Principal Investigators

  • Caroline Breitbach, PhD · Turnstone Biologics, Corp.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-08
Primary Completion
2020-02-15
Completion
2020-05-24

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02879760 on ClinicalTrials.gov